{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:09:23Z","timestamp":1793164163009,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["101137405"],"award-info":[{"award-number":["101137405"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF23OC0085944"],"award-info":[{"award-number":["NNF23OC0085944"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF23OC0084420"],"award-info":[{"award-number":["NNF23OC0084420"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024-03401"],"award-info":[{"award-number":["2024-03401"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-02801"],"award-info":[{"award-number":["2021-02801"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2023-03015"],"award-info":[{"award-number":["2023-03015"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100346","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:48:30Z","timestamp":1782143310000},"page":"100346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids\u2014Application to recent real-world cases"],"prefix":"10.1016","volume":"54","author":[{"given":"Yufeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongda","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kukasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Youhanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2807-1316","authenticated-orcid":false,"given":"Sabine U.","family":"Vorrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-0730","authenticated-orcid":false,"given":"Anne T.","family":"Nies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9099-4791","authenticated-orcid":false,"given":"Julia","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"K\u00f6lz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhye","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-278X","authenticated-orcid":false,"given":"Nayere","family":"Taebnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-2773","authenticated-orcid":false,"given":"Kathrin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-9656","authenticated-orcid":false,"given":"Oliver","family":"Burk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-6204","authenticated-orcid":false,"given":"Volker M.","family":"Lauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.dmd.2026.100346_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16146","article-title":"Epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs","volume":"45","author":"Suzuki","year":"2025","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.dmd.2026.100346_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmd.2026.100346_bib4","article-title":"The incidence of chronic drug-induced liver injury: a systematic review and meta-analysis","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100346_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41573-019-0048-x","article-title":"Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models","volume":"19","author":"Weaver","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.dmd.2026.100346_bib6","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/ijms17101714","article-title":"The importance of patient-specific factors for hepatic drug response and toxicity","volume":"17","author":"Lauschke","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.dmd.2026.100346_bib7","doi-asserted-by":"crossref","DOI":"10.21037\/atm-2020-ubih-05","article-title":"Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues","volume":"9","author":"Teschke","year":"2021","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.dmd.2026.100346_bib8","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/hep.28780","article-title":"Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation","volume":"64","author":"Lauschke","year":"2016","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.dmd.2026.100346_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bcpt.13587","article-title":"3D human liver spheroids for translational pharmacology and toxicology","volume":"130","author":"Ingelman-Sundberg","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100346_bib10","article-title":"Liver three-dimensional cellular models for high-throughput chemical testing","volume":"3","author":"Yang","year":"2023","journal-title":"Cell Rep Methods"},{"key":"10.1016\/j.dmd.2026.100346_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eng.2025.01.019","article-title":"Organoids and organ-on-chip models for COVID-19 research and its application in modernization of traditional Chinese medicine: opportunities and challenges","volume":"54","author":"Sheng","year":"2025","journal-title":"Engineering"},{"issue":"7","key":"10.1016\/j.dmd.2026.100346_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201800347","article-title":"3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications","volume":"14","author":"Lauschke","year":"2019","journal-title":"Biotechnol J"},{"issue":"8","key":"10.1016\/j.dmd.2026.100346_bib13","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00204-017-2002-1","article-title":"Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury","volume":"91","author":"Proctor","year":"2017","journal-title":"Arch Toxicol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100346_bib14","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.xphs.2020.02.021","article-title":"Three-dimensional spheroids with primary human liver cells and differential roles of Kupffer cells in drug-induced liver injury","volume":"109","author":"Li","year":"2020","journal-title":"J Pharmac Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100346_bib15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/toxsci\/kfy058","article-title":"Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions","volume":"163","author":"Vorrink","year":"2018","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.dmd.2026.100346_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.namjnl.2025.100075","article-title":"Set up of a human 3D liver multicellular model for chemical high-throughput toxic hazard assessment","volume":"2","author":"Recoules","year":"2026","journal-title":"NAM J"},{"key":"10.1016\/j.dmd.2026.100346_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2020.611913","article-title":"Current perspective: 3D spheroid models utilizing human-based cells for investigating metabolism-dependent drug-induced liver injury","volume":"2","author":"Cox","year":"2020","journal-title":"Front Med Technol"},{"key":"10.1016\/j.dmd.2026.100346_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.dmd.2026.100346_bib19","series-title":"Pfizer provides update on oral GLP-1 receptor agonist danuglipron","year":"2025"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.16005","article-title":"Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: a dose-ranging, phase 2, randomized, placebo-controlled study","volume":"27","author":"Amin","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/srep25187","article-title":"Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease","volume":"6","author":"Bell","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/srep35434","article-title":"Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability","volume":"6","author":"Hendriks","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmd.2026.100346_bib23","article-title":"Single-cell resolution three-dimensional imaging of intact organoids","volume":"160","author":"Van Ineveld","year":"2020","journal-title":"J Vis Exp"},{"key":"10.1016\/j.dmd.2026.100346_bib24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"10.1016\/j.dmd.2026.100346_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.116.074369","article-title":"Transcriptional, functional, and mechanistic comparisons of stem cell\u2013derived hepatocytes, HepaRG cells, and three-dimensional human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury","volume":"45","author":"Bell","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100346_bib26","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1096\/fj.201601375R","article-title":"Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics","volume":"31","author":"Vorrink","year":"2017","journal-title":"FASEB J"},{"issue":"15","key":"10.1016\/j.dmd.2026.100346_bib27","article-title":"A 3D cell culture model identifies Wnt\/\u03b2-catenin mediated inhibition of p53 as a critical step during human hepatocyte regeneration","volume":"7","author":"Oliva-Vilarnau","year":"2020","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"10.1016\/j.dmd.2026.100346_bib28","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00204-020-02682-w","article-title":"Functionality of primary hepatic non-parenchymal cells in a 3D spheroid model and contribution to acetaminophen hepatotoxicity","volume":"94","author":"Bell","year":"2020","journal-title":"Arch Toxicol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100346_bib29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40262-022-01119-0","article-title":"Liver cirrhosis affects the pharmacokinetics of the six substrates of the basel phenotyping cocktail differently","volume":"61","author":"Duthaler","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2026.100346_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/tx034033e","article-title":"Mechanisms of troglitazone hepatotoxicity","volume":"16","author":"Smith","year":"2003","journal-title":"Chem Res Toxicol"},{"issue":"19","key":"10.1016\/j.dmd.2026.100346_bib31","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/01.CIR.100.19.2025","article-title":"Evidence-based analysis of amiodarone efficacy and safety","volume":"100","author":"Connolly","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib32","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1186\/s12885-018-4891-7","article-title":"Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hep.23647","article-title":"Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells","volume":"52","author":"Blas-Garc\u00eda","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dmd.2026.100346_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.taap.2011.09.008","article-title":"Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes","volume":"257","author":"Bumpus","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmd.2026.100346_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7453406","article-title":"Elucidation of the molecular mechanisms underlying sorafenib-induced hepatotoxicity","volume":"2020","author":"AlAsmari","year":"2020","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"10.1016\/j.dmd.2026.100346_bib36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/jpet.121.000828","article-title":"Novel bile acid-dependent mechanisms of hepatotoxicity associated with tyrosine kinase inhibitors","volume":"380","author":"Saran","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.4.1.69","article-title":"Tolcapone in Parkinson\u2019s disease: liver toxicity and clinical efficacy","volume":"4","author":"Borges","year":"2005","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/psp4.12053","article-title":"Elucidating differences in the hepatotoxic potential of tolcapone and entacapone with DILIsym\u00ae, a mechanistic model of drug-induced liver injury","volume":"5","author":"Longo","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100346_bib39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0887-2333(95)00035-7","article-title":"Molecular mechanism of diclofenac hepatotoxicity: association of cell injury with oxidative metabolism and decrease in ATP levels","volume":"9","author":"Ponsoda","year":"1995","journal-title":"Toxicol In Vitro"},{"issue":"4","key":"10.1016\/j.dmd.2026.100346_bib40","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/BF01316809","article-title":"Diclofenac induced hepatitis: 3 cases with features of autoimmune chronic active hepatitis","volume":"38","author":"Scully","year":"1993","journal-title":"Digest Dis Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100346_bib41","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/hep.510290535","article-title":"Hepatotoxicity of psychotropic drugs","volume":"29","author":"Selim","year":"1999","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.dmd.2026.100346_bib42","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.dmd.2026.100346_bib43","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.dmd.2026.100346_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/dmd.123.001302","article-title":"Individualized pharmacotherapy utilizing genetic biomarkers and novel in vitro systems as predictive tools for optimal drug development and treatment","volume":"52","author":"Ingelman-Sundberg","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100346_bib45","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/clpt.2013.143","article-title":"Association of CYP2C9\u22172 with bosentan-induced liver injury","volume":"94","author":"Markova","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00204-016-1694-y","article-title":"Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile","volume":"91","author":"Heslop","year":"2017","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.dmd.2026.100346_bib47","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3389\/fphys.2020.00950","article-title":"Neurotropin inhibits lipid accumulation by maintaining mitochondrial function in hepatocytes via AMPK activation","volume":"11","author":"Wang","year":"2020","journal-title":"Front Physiol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100346_bib48","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/cells11050866","article-title":"An optimized workflow for the analysis of metabolic fluxes in cancer spheroids using seahorse technology","volume":"11","author":"Campioni","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.dmd.2026.100346_bib49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/15376516.2024.2447740","article-title":"HepG2 spheroids cultured in alginate microcapsules as a model for exploring mitochondrial and glycolytic metabolism using the Seahorse XFe24 Analyzer","volume":"35","author":"Ghiraldelli Miranda","year":"2025","journal-title":"Toxicol Mech Methods"},{"key":"10.1016\/j.dmd.2026.100346_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108824","article-title":"GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?","volume":"269","author":"Arredouani","year":"2025","journal-title":"Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.dmd.2026.100346_bib51","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dmd.2026.100346_bib52","series-title":"BioAge labs announces discontinuation of STRIDES phase 2 clinical trial evaluating azelaprag in combination with tirzepatide for the treatment of obesity","year":"2024"},{"issue":"5","key":"10.1016\/j.dmd.2026.100346_bib53","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cpt.3185","article-title":"Safety, tolerability, and pharmacokinetics of an oral small molecule inhibitor of IL-17A (LY3509754): a phase I randomized placebo-controlled study","volume":"115","author":"Datta-Mannan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100346_bib54","doi-asserted-by":"crossref","DOI":"10.1289\/EHP11891","article-title":"Mapping interindividual variability of toxicodynamics using high-throughput transcriptomics and primary human hepatocytes from fifty donors","volume":"132","author":"Niemeijer","year":"2024","journal-title":"Environ Health Perspect"},{"issue":"2","key":"10.1016\/j.dmd.2026.100346_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/toxsci\/kfx289","article-title":"Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study","volume":"162","author":"Bell","year":"2018","journal-title":"Toxicol Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100346_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100230","article-title":"Influence of 3-dimensional architecture and coculture on in vitro CYP enzyme metabolism and induction: benchmarking human hepatic spheroids for studies in drug development","volume":"54","author":"Lenich","year":"2026","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100346_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1208\/s12248-022-00689-y","article-title":"Multi-well array culture of primary human hepatocyte spheroids for clearance extrapolation of slowly metabolized compounds","volume":"24","author":"Preiss","year":"2022","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.dmd.2026.100346_bib58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/03602532.2011.604086","article-title":"Central role of mitochondria in drug-induced liver injury","volume":"44","author":"Pessayre","year":"2012","journal-title":"Drug Metabol Rev"},{"issue":"5","key":"10.1016\/j.dmd.2026.100346_bib59","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jhep.2023.01.019","article-title":"A human liver organoid screening platform for DILI risk prediction","volume":"78","author":"Zhang","year":"2023","journal-title":"J Hepatol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600615X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600615X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:53:52Z","timestamp":1791996832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562600615X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S009095562600615X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100346","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids\u2014Application to recent real-world cases","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100346"}}